Company profile
REVELATION BIOSCIENCES, INC.
NASDAQ:REVBBiotechnology: Pharmaceutical Preparations
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06863467 | phase1_2 | completed | 2025-01-20 | 2025-07-22 | Revelation Biosciences, Inc | Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease. |
FDA applications (0)
No records yet.